B of A Securities Maintains Neutral on Amgen, Raises Price Target to $330
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Geoff Meacham maintains a Neutral rating on Amgen (NASDAQ:AMGN) and raises the price target from $325 to $330.
August 07, 2024 | 5:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
B of A Securities analyst Geoff Meacham maintains a Neutral rating on Amgen and raises the price target from $325 to $330.
The raised price target from $325 to $330 indicates a slightly more positive outlook on Amgen's stock, which could lead to a minor positive impact on the stock price in the short term. However, the Neutral rating suggests limited upside potential.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100